Sales Reach 392.9 Billion Won, Operating Profit at 53.6 Billion Won
Net Profit Up 14% Year-on-Year
R&D Investment Tops 65.2 Billion Won, Exceeding Last Year’s Full-Year Ratio
Rosuzet and Beijing Hanmi Drive Growth
Key Clinical Trial Milestones Accelerate

Hanmi Pharmaceutical continued to invest in research and development (R&D) at the 16% level relative to first-quarter sales.


Hanmi Group corporate logo image. Hanmi Group

Hanmi Group corporate logo image. Hanmi Group

View original image

On April 30, Hanmi Pharmaceutical announced through a regulatory filing that it posted sales of 392.9 billion won and operating profit of 53.6 billion won in the first quarter. Net profit was 51.1 billion won, marking a 14.4% increase year-on-year.


The R&D investment amounted to 65.2 billion won, which is 16.6% of sales. This figure is higher than last year’s full-year R&D ratio of 14.8%. Although sales have increased, the company also raised its investment proportion.


Performance was driven by the prescription drug sector and growth in its Chinese subsidiary. Outpatient prescription drug sales totaled 277.6 billion won. The dyslipidemia treatment Rosuzet recorded the highest sales contribution at 59.3 billion won, followed by the Amozaltan Family at 36.4 billion won, and the Esomezol Family at 14.6 billion won.


Beijing Hanmi Pharmaceutical, the Chinese subsidiary, posted sales of 106.4 billion won and operating profit of 23.6 billion won. Sales grew by 10.3%, while operating profit and net profit increased by 107.7% and 119.2%, respectively.


Hanmi Fine Chemical, an affiliate specializing in active pharmaceutical ingredients, reported sales of 21.7 billion won, and saw its operating profit return to the black thanks to the expansion of its CDMO orders.


Hanmi Pharmaceutical currently operates around 30 new drug pipelines in areas such as obesity, metabolic disease, cancer, and rare diseases. Key clinical trial milestones, including the commercialization of the GLP-1 obesity treatment Efpeglenatide, are concentrated this year.


Sangyeon Hwang, CEO of Hanmi Pharmaceutical, stated, “This year is expected to be significant for Hanmi as we confirm progress in various new drug development fields we have pursued. All our employees will unite and strive for greater leaps forward with a goal of delivering innovative results.”





This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing